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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.04.030Objective: As a result of increasing discovery of small-sized lung cancer in clinical
practice, tumor size has come to be considered an important variable affecting
planning of treatment. Nevertheless, there have been no reports including large
numbers of patients and focusing on tumor size, and controversy remains concern-
ing the surgical management of small-sized tumors. Therefore, we investigated the
relationships between tumor dimension and clinical and follow-up data, as well as
surgical procedure in particular.
Methods: We reviewed the records of 1272 consecutive patients who underwent
complete resection for non–small cell carcinoma of the lung.
Results: Fifty patients had tumors of 10 mm or less, 273 had tumors of 11 to 20 mm,
368 had tumors of 21 to 30 mm, and 581 had tumors of greater than 30 mm in
diameter. The cancer-specific 5-year survivals of patients in these 4 groups were
100%, 83.5%, 76.5%, and 57.9%, respectively. For patients with pathologic stage I
disease, they were 100%, 92.6%, 84.1%, and 76.4%, respectively. Multivariate
analysis demonstrated that male sex, older age, larger tumor, and advanced patho-
logic stage adversely affected survival. Lesser resection was performed in 167
(52%) of 323 patients with a tumor of 20 mm or less in diameter but in 156 (16%)
of 949 patients with a tumor of greater than 20 mm in diameter. The percentages of
lesser resection among all procedures performed were 79%, 56%, 30%, and 15% in
patients with pathologic stage I disease with a tumor of 10 mm or less, 11 to 20 mm,
21 to 30 mm, and greater than 30 mm in diameter, respectively. The 5-year
cancer-specific survivals of patients with pathologic stage I disease with tumors of
20 mm or less and 21 to 30 mm in diameter were 92.4% and 87.4% after lobectomy,
96.7% and 84.6% after segmentectomy, and 85.7% and 39.4% after wedge resec-
tion, respectively. On the other hand, with a tumor of greater than 30 mm in
diameter, survivals were 81.3% after lobectomy, 62.9% after segmentectomy, and
0% after wedge resection, respectively.
Conclusions: Tumor size is an independent and significant prognostic factor and
important for planning of surgical treatment. Although lobectomy should be chosen
for patients with a tumor of greater than 30 mm in diameter, further investigation is
required for tumors of 21 to 30 mm in diameter. Segmentectomy should, as a lesser
anatomic resection, be distinguished from wedge resection and might be acceptable
for patients with a tumor of 20 mm or less in diameter without nodal involvement.
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TSOf late, as a consequence of advances indiagnostic imaging, such as high-resolu-tion or spiral computed tomography andpositron emission tomographic scanning,thoracic surgeons have encounteredsmall-sized lung cancers at an earlier and
potentially curable stage. It has thus become increasingly
crucial to examine how clinical and oncologic behaviors are
related to tumor dimension and thereby to choose the most
advantageous treatment strategy, including surgical inter-
vention. Although the traditional TNM staging system ex-
ists,1 it might become obsolete within a few years and
should be revised with new findings. As stated by the TNM
system, the boundary of T status is a tumor 3 cm in diam-
eter. Recent studies have, however, demonstrated that the
postoperative prognosis of patients with non–small cell lung
cancer of 2 cm or less in diameter is significantly better than
that of patients with a larger tumor.2-5 Controversy also
exists regarding the extent of lung removal necessary for
cure, especially for small-sized cancers. Although lobec-
tomy or pneumonectomy has traditionally been considered
the standard of care for resectable disease, the significance
of lesser resection in the treatment of early non–small cell
cancer has attracted increased interest as a minimally inva-
sive operation with the advancement of video-assisted tho-
racic surgery. Arguments favoring the less-invasive opera-
tion include potential preservation of pulmonary function,
lower morbidity-mortality, and shorter hospitalization. Sur-
prisingly, there are no reports of large numbers of patients
focusing on tumor dimension, one of the most subjective
reoperative variables. Thus, newer information for selection
of surgical intervention on the basis of tumor size is re-
quired.
We evaluated the role of tumor size, which has had
increased clinical importance because of the increasing dis-
covery of small-sized lung cancer in clinical practice. The
aims of this study were to compare the clinical characteris-
tics and follow-up data of patients subjected to complete
resection of non–small cell lung cancer with tumor dimen-
sion, with special reference to determination of the appro-
priate surgical mode of treatment.
Patients and Methods
Between January 1985 and December 2002, a series of 1272
consecutive patients operated on for primary non–small cell
carcinoma of the lung were pathologically confirmed to
have complete removal with systematic nodal dissection of
the hilum and mediastinum. Institutional review board ap-
proval was obtained for collection of their data in a secure
database and reporting of analyses of that data. The histo-
logic type of the tumor was determined by the World Health
Organization classification. Patients with low-grade malig-
nancy of the lung, such as carcinoid, were excluded. Staging
88 The Journal of Thoracic and Cardiovascular Surgery ● Januawas determined according to the international TNM staging
system. Patients who had been subjected to preoperative
chemotherapy or radiotherapy were excluded.
The maximum dimension of a tumor was measured using
resected primary lesion specimens. Generally, the patients
were postoperatively examined at 3-month intervals for 5
years and thereafter at 1-year intervals to check for recur-
rence and survival. We used physical and biochemical ex-
amination, chest radiography, computed tomography of the
chest, brain, and upper portion of the abdomen, and bone
scintigraphy for evaluation of recurrence.
Survivals were calculated by the Kaplan-Meier method,
and differences in survival were determined by log-rank
analysis. A multivariate analysis for prognostic factors was
carried out by the Cox proportional hazards regression
model. We analyzed the prognosis of patients in two fash-
ions, to determine overall and cancer-related survivals. Zero
time was the date of pulmonary resection, and the terminal
event was death attributable to cancer-related survival, al-
though the terminal point for overall survival was any death
due to cancer, noncancerous, or unknown causes.
Results
Patients were divided into 4 groups for comparison by size
of resected tumor. Fifty patients had a primary tumor with
a diameter of 10 mm or less, 273 patients had a tumor of 11
to 20 mm, 368 patients had a tumor of 21 to 30 mm, and 581
patients had a tumor of greater than 30 mm in diameter.
Clinical characteristics, pathologic stage, and surgical mode
are summarized in Table 1, which shows that larger lesions
had high degrees of association with old age, male sex,
squamous cell carcinoma, and advanced-stage disease. No-
tably, half of the patients with a subcentimeter tumor were
female, 70% of the patients had adenocarcinoma, and 96%
had pathologic stage IA disease, although 4% had stage III
disease. Larger resections were, as a general rule, selected
for larger lesions. On the other hand, lesser resections, such
as segmentectomy, were preferred for smaller lesions with-
out proof of nodal involvement, as determined by intraop-
erative pathologic examination. As a result, lesser resections
were performed in 167 (52%) of 323 patients with a tumor
of 20 mm or less in diameter and in 156 (16%) of 949
patients with a tumor of greater than 20 mm in diameter. Of
50 patients with subcentimeter cancer, 38 (76%) underwent
lesser resection, including 27 (54%) with segmentectomy.
There were 3 (3/1272 [0.2%]) operative deaths. Causes of
death were acute pancreatitis and bleeding during reopera-
tion. The third patient died suddenly at home on the 30th
postoperative day as a result of myocardial infarction. Fol-
low-up was almost complete and ranged from 12 to 225
months, with a median of 61 months for surviving patients.
The overall 5-year survivals of patients with a tumor of 10
mm or less, 11 to 20 mm, 21 to 30 mm, and greater than 30
ry 2005
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TSmm in diameter were 87.3%, 75.5%, 68.0%, and 49.0%,
respectively (Figure 1, A), whereas the corresponding can-
cer-specific 5-year survivals were 100%, 83.5%, 76.5%, and
TABLE 2. Multivariate analyses for overall and cancer-
non–small cell lung cancer
Factors Unfavorable Favorable
Prognosis for overall deaths
Sex Male Female
Age Older Younger
Size Larger Smaller
Histology Non-AD AD
P-stage Advanced Early
Procedure PNLO SEWEBR
Prognosis for cancer-specific deaths
Sex Male Female
Age Older Younger
Size Larger Smaller
Histology Non-AD AD
P-stage Advanced Early
Procedure PNLO SEWEBR
CI, Confidence interval; AD, adenocarcinoma; PN, pneumonectomy; LO, lo
Continuous variables for age, size, and p-stage, and categories for gende
TABLE 1. Characteristics of patients with complete resec
surgical interventions according to tumor size
Tumor size (mm)
<10
(n  50)
11-20
(n  273)
Age (y) 62 (40-79) 64 (38-85)
Sex
Male 25 (50%) 170 (62%)
Female 209 (77%) 254 (69%)
Average size (mm) 7.5 16.7
Histology
AD 35 (70%) 209 (77%)
SQ 15 (30%) 61 (22%)
LA 0 3 (1%)
Pathologic stage
IA 48 (96%) 208 (76%)
IB 0 9 (3%)
IIA 0 21 (8%)
IIB 0 5 (2%)
IIIA 1 (2%) 23 (8%)
IIIB 1 (2%) 7 (3%)
Procedure
PN 0 2 (1%)
LO 12 (24%) 142 (52%)
SE 27 (54%) 102 (37%)
WE 10 (20%) 27 (10%)
BR 1 (2%) 0
AD, Adenocarcinoma; SQ, squamous cell carcinoma; LA, large cell carc
resection; BR, bronchial resection.57.9%, respectively (Figure 1, B). There were significant
The Journal of Thoracdifferences in survivals among the 4 groups. Additionally,
for patients with pathologic stage I disease, the overall
5-year survivals of the 4 groups noted above were 86.0%,
ific prognosis in patients with complete resection for
Risk ratio 95% CI P value
1.772 1.397-2.247 .0001
1.030 1.019-1.042 .0001
1.003 1.001-1.005 .0035
1.059 0.874-1.284 .5587
2.027 1.821-2.257 .0001
1.049 0.818-1.345 .7039
1.569 1.184-2.078 .0017
1.014 1.001-1.027 .0387
1.004 1.002-1.006 .0001
1.136 0.894-1.443 .2969
2.430 2.129-2.773 .0001
1.047 0.761-1.442 .7763
my; SE, segmentectomy; WE, wedge resection; BR, bronchial resection.
tology and procedures are given.
for non–small cell lung cancer, pathologic findings, and
21-30
(n  368)
>31
(n  581)
Total
(n  1272)
65 (36-85) 65 (30-85) 65 (30-88)
249 (68%) 455 (78%) 899 (71%)
284 (49%) 782 (61%)
25.8 47.6 33.1
254 (69%) 284 (49%) 782 (61%)
105 (29%) 275 (47%) 456 (36%)
9 (2%) 2 (0.3%) 34 (3%)
233 (63%) 0 489 (38%)
2 (1%) 258 (44%) 289 (23%)
42 (11%) 0 63 (5%)
18 (5%) 141 (24%) 164 (13%)
39 (11%) 129 (22%) 192 (15%)
14 (4%) 53 (9%) 75 (6%)
5 (1%) 23 (4%) 30 (2%)
268 (73%) 497 (86%) 919 (72%)
76 (21%) 53 (9%) 258 (20%)
19 (5%) 8 (1%) 64 (5%)
0 0 1 (0.1%)
; PN, pneumonectomy; LO, lobectomy; SE, segmentectomy; WE, wedgespec
bectotion
inoma83.8%, 75.3%, and 67.0%, respectively (Figure 2, A),
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92.6%, 84.1%, and 76.4%, respectively (Figure 2, B). There
were significant differences in these survivals between pa-
tients with a tumor of 11 to 20 mm in diameter and those
with a tumor of 21 to 30 mm in diameter.
Univariate analyses demonstrated that male sex (P 
.0001), age older than 65 years (P  .0003), tumor size
larger than 30 mm (P  .0001), nonadenocarcinoma (P 
.0004), advanced pathologic stage (P  .0001), and formal
resections, including lobectomy and pneumonectomy (P 
.0014), significantly and negatively affected overall sur-
vival. Next we performed multivariate analyses for progno-
sis by using these key variables (Table 2) and found that
male sex, older age, larger tumor, and advanced pathologic
stage adversely affected overall and cancer-specific surviv-
Figure 1. Overall (A) and cancer-specific (B) survival
cell lung cancer according to tumor size.als, whereas neither histology nor surgical procedure sig-
90 The Journal of Thoracic and Cardiovascular Surgery ● Januanificantly influenced survival on stratification by other vari-
ables.
We examined the relationships between surgical mode
and tumor size and their association with postoperative
survival. The percentages of lesser resection among all
procedures completed were 79% (38/48), 56% (121/217),
30% (78/255), and 15% (40/258) in patients with stage I
disease with a tumor of 10 mm or less, 11 to 20 mm, 21 to
30 mm, and greater than 30 mm in diameter, respectively.
Although only patients without nodal involvement were
included in these survival analyses, there were no cancer-
specific deaths in patients with a tumor of 10 mm or less in
diameter, irrespective of surgical mode. The 5-year cancer-
specific survivals of patients with stage I disease with a
tumor of 20 mm or less in diameter were 96.7% after
s for patients with complete resection for non–smallcurvesegmentectomy, 92.4% after lobectomy, and 85.7% after
ry 2005
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differences between these procedures. In addition, the
5-year cancer-specific survivals of patients with stage I
disease with a tumor of 21 to 30 mm in diameter were
87.4% after lobectomy, 84.6% after segmentectomy, and
39.4% after wedge resection (Figure 3, B). There were
significant differences between wedge resection and the
other modes but not between lobectomy and segmentec-
tomy. In patients with stage I disease with a tumor of greater
than 30 mm in diameter, the 5-year cancer-specific survivals
were 81.3% after lobectomy, 62.9% after segmentectomy,
and 0% after wedge resection (Figure 3, C). There were
significant differences between all matchings.
Discussion
Tumor dimension was clearly shown to be a significant pre-
dictor of survival not only by univariate analysis but also by
Figure 2. Overall (A) and cancer-specific (B) survival
stage I non–small cell lung cancer according to tumomultivariate analysis. In the present international TNM staging
The Journal of Thoracsystem, the cutoff value of T factor (tumor size) is 30 mm,1
which is a contentious problem. In addition to reports that
patients with a tumor of 2 cm or less in diameter had a better
survival than those with a tumor of 2.1 to 3.0 cm in diameter,4,6
we demonstrated that patients with a tumor of 11 to 20 mm in
diameter had significantly better overall and cancer-specific
survivals than those with a tumor of 21 to 30 mm in diameter
among patients with completely resected pathologic stage I
tumors excluding lymph node involvement, but there were no
significant differences in overall or cancer-specific survivals
between patients with a tumor of 21 to 30 mm in diameter and
those with a tumor of larger than 30 mm in diameter. These
findings suggest that 20 mm is preferable as a cutoff value for
T factor in staging.
Tumor size was not the only factor that affected prog-
nosis after complete resection. Additionally, sex, age, his-
tologic type, pathologic stage, and operative procedure sig-
s for patients with complete resection for pathologic
.curvenificantly affected survival on univariate tests. Surprisingly,
ic and Cardiovascular Surgery ● Volume 129, Number 1 91
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cluded lobectomy and pneumonectomy, was worse than that
after lesser operations, probably because we tended to re-
move less lung parenchyma for earlier-stage cancers. To
certify this hypothesis, we evaluated the relationships be-
tween operative procedure and survival on multivariate
tests, which were unable to correlate the 2 factors. A total of
4% of our patients were found to have any advanced factor,
even though tumors measured 10 mm or less in diameter. In
our series, tumors of 11 to 20 mm and 21 to 30 mm in
diameter had 21% and 36% advanced factors, respectively,
whereas 56% of tumors greater than 30 mm in diameter
were associated with higher-stage disease. Others have ob-
tained similar results.3,7 Supporters of lesser resection in
noncompromised patients maintain that even for small-sized
Figure 3. Cancer-specific survival curves for patients
cell lung cancer of 20 mm or less (A), 21 to 30 mm (B),
procedure.tumors there is minimal risk of advanced disease, such as
92 The Journal of Thoracic and Cardiovascular Surgery ● Januanodal involvement, and that it might be essential to identify
risks preoperatively or intraoperatively. The proportions of
lesser resection in the total procedures were 74% (37/50),
47% (129/273), and 26% (95/368) for patients with a tumor
of 10 mm or less, 11 to 20 mm, and 21 to 30 mm in
diameter, respectively; when limited to patients with stage I
disease, they were 79% (38/48), 56% (121/217), and 30%
(78/255), respectively. We have always maintained the pol-
icy that removal of lung parenchyma should deliberately be
reduced as long as oncologic radicality can be preserved. In
this study we analyzed follow-up data in terms of overall
survival and cancer-specific survival and believe the latter is
probably more appropriate for examination of results. If
there is essentially no statistically significant difference in
cancer-specific survival between lobectomy and lesser re-
complete resection for pathologic stage I non–small
reater than 30 mm in diameter according to operativewith
and gsection, and the 5-year survivals with the 2 types of proce-
ry 2005
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tomy is better?
Since 1992, at our institute we have, as a prospective
trial, tried segmentectomy with lymph node dissection in
noncompromised patients with stage IA non–small cell lung
cancer of 2 cm or smaller in diameter who had undergone
lobectomy up to that time.2,8,9 Continuing controversy ex-
ists concerning the role of segmentectomy but not that of
wedge resection in noncompromised patients with primary
lung cancer, although it is not debated for benign diseases,
metastatic tumors, or selected primary cancers in compro-
mised patients. In 1995, lobectomy had been confirmed to
be a standard procedure of choice for tumors of any size.10
However, several sequential studies, including prospective
ones, have shown the usefulness of segmentectomy for
small-sized N0 cancer.2,8,9,11-13 Thus, current persuasive
data suggest that for smaller N0 cancers, segmentectomy
might be an acceptable surgical method, even in noncom-
promised patients.
In our series the frequency of segmentectomy was 5
times that of wedge resection. It was impossible to overem-
phasize the percentages of segmentectomy in all lesser
resections. Because segmentectomy and wedge resection
have thus far been combined and categorized together as
types of lesser resection, we cannot evaluate the 2 proce-
dures separately on the basis of results in the literature. We
believe that segmentectomy is an anatomic procedure in
which lymph nodes can be examined at various levels of
N1. Some reports, as well as our own experience, have
shown nonanatomic wedge resection to be inferior to ana-
tomic segmentectomy.12,14 Segmentectomy should be care-
fully distinguished from wedge resection in practice and
clinical research, as in this study. Recently, few segmentec-
tomies are being performed and many thoracic surgeons are
not familiar with this useful method.15 Although technically
more challenging than other resections, segmentectomy is
valuable and should be kept in mind by younger thoracic
surgeons.
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